...
首页> 外文期刊>BJU international >Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor.
【24h】

Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor.

机译:肾细胞癌中微血管肿瘤浸润:最重要的预后因素。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE To evaluate the role of microvascular invasion (MVI) in the primary lesion for predicting tumour behaviour in patients with renal cell carcinoma (RCC), as reliable clinical prognostic factors would be very valuable. PATIENTS AND METHODS MVI was assessed in 230 patients with clinically localized RCC (stages T1-4NxM0) who had a radical nephrectomy and/or nephron-sparing surgery. The median (range) follow-up was 48 (3-130) months. The impact of MVI on disease progression and its correlation with clinical and histopathological factors was analysed, including whether patients were symptomatic or not at presentation, Fuhrman nuclear grade, tumour size, pathological stage and lymph node metastasis. Regression analyses and survival curves were used to determine if MVI was associated with the prognosis of RCC. RESULTS There was MVI in 59 patients (26%); of these, 46% developed disease recurrence. Among the 171 patients with no MVI, only 11 (6%) had tumour recurrence. MVI was associated with tumour diameter, nuclear grade, pathological stage, lymph node metastasis and the presence of sarcomatous elements in the tumour. Multivariate analysis showed that MVI was an independent predictor of disease recurrence and the most important factor related to death. CONCLUSION MVI is an independent predictor of prognosis in patients with RCC.
机译:目的评估微血管浸润(MVI)在原发灶中对预测肾细胞癌(RCC)患者肿瘤行为的作用,因为可靠的临床预后因素将非常有价值。患者与方法对230例行根治性肾切除术和/或保肾术的RCC临床患者(T1-4NxM0期)进行了MVI评估。中位(范围)随访为48(3-130)个月。分析了MVI对疾病进展的影响及其与临床和组织病理学因素的相关性,包括患者是否有症状,福尔曼核分级,肿瘤大小,病理分期和淋巴结转移。回归分析和生存曲线用于确定MVI是否与RCC的预后相关。结果59例患者中有MVI(26%)。其中,46%发生疾病复发。在171例无MVI的患者中,只有11例(6%)有肿瘤复发。 MVI与肿瘤直径,核分级,病理分期,淋巴结转移和肿瘤中肉瘤元素的存在有关。多变量分析表明,MVI是疾病复发的独立预测因子,并且是与死亡相关的最重要因素。结论MVI是RCC患者预后的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号